Skip to main content
Contact Us
Subscribe
E-Edition
59°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Enzolytics, Inc.
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
July 28, 2022
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
ENZC
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
June 21, 2022
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tickers
ENZC
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans
April 25, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics, Inc. Reports Progress and Future Plans
April 25, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics IPF Immune(TM) Introduced to Large and Small Retail Buyers at Recent ECRM "Weight Management, Nutrition, and Vitamin Program"
April 11, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
March 25, 2022
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
ENZC
Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements
March 23, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions
March 14, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month
March 10, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics, Inc. Announces New Advisory Board Member
February 28, 2022
From
Enzolytics, Inc.
Via
AccessWire
Tickers
ENZC
Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market
February 21, 2022
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Tickers
ENZC
Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System
January 04, 2022
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ENZC
Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic
December 29, 2021
From
Enzolytics, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
ENZC
Enzolytics Announces Progress As It Recognizes World AIDS Day
December 02, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Intellectual Property
Tickers
ENZC
Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
November 17, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
ENZC
Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology
November 08, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
July 29, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Lead
Legal
Tickers
ENZC
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
July 26, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
ENZC
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
July 21, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
July 20, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
June 14, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Tickers
ENZC
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
June 07, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Intellectual Property
Tickers
ENZC
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
May 26, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
May 17, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Fraud
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
May 12, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
ENZC
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
May 11, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
ENZC
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
April 19, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Tickers
ENZC
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
April 12, 2021
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
ENZC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.